Cleveland BioLabs downgraded to Perform from Outperform at Oppenheimer Oppenheimer downgraded Cleveland BioLabs calling BARDA's decision to terminate negotiations for the continued development of Entolimod a significant setback.
News For CBLI From The Last 14 Days
Check below for free stories on CBLI the last two weeks.
Cleveland BioLabs to submit pre-EUA application for entolimod Cleveland BioLabs announced that the minutes from its meeting with the FDA in July confirmed that the company's existing efficacy and safety data and animal-to-human dose conversion are sufficient to proceed with a pre-Emergency Use Authorization, or pre-EUA, submission for entolimod for reducing the risk of death following exposure to potentially lethal irradiation occurring as the result of a radiation disaster. The FDA has granted Fast Track status to entolimod and Orphan Drug status for prevention of death following a potentially lethal dose of total body irradiation during or after a radiation disaster.